PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion

Yen Han Tseng, Hsiang Ling Ho, Chiung Ru Lai, Yung Hung Luo, Yen Chiang Tseng, Jacqueline Whang-Peng, Yi hsuan Lin, Teh Ying Chou, Yuh Min Chen

研究成果: 雜誌貢獻文章

9 引文 斯高帕斯(Scopus)


Introduction: Whether immunohistochemical staining of programmed death ligand 1 (PD-L1) on cells of pleural effusion could be used to predict response to immunotherapy treatment has not been reported. Methods: We retrospectively enrolled patients who had undergone malignant pleural effusion drainage and had effusion cell block specimens from 2014 to 2016. Immunohistochemical staining for PD-L1 was performed with tumor cells, immune cells, and macrophages of all cell block specimens. Immunoactivity was scored as 0 for absence of staining and 1+ for faint, 2+ for moderate, and 3+ for intense membranous staining. Patients’ clinicopathological characteristics were also collected. Results: PD-L1 expression of pleural effusion tumor cells was associated with the PD-L1 expression of macrophages (p = 0.003) and immune cells (p < 0.001). However, the PD-L1 expression of immune cells was not associated with that of macrophages. The PD-L1 expression of tumor cells was correlated with sex (p = 0.012), smoking status (p = 0.032), and Eastern Cooperative Oncology Group performance status (p = 0.017). The PD-L1 expression of immune cells was associated with the overall survival of patients (p = 0.004). Conclusions: These results suggest that there might be an immune interaction between pleural effusion tumor cells and macrophages. The low intensity of PD-L1 expression in immune cells is associated with the poor survival of patients with lung cancer with malignant pleural effusion.

頁(從 - 到)447-453
期刊Journal of Thoracic Oncology
出版狀態已發佈 - 三月 1 2018


ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine